Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer.
The rally is outpacing fellow vaccine names Pfizer (NYSE:PFE), up 2% near $26.10, and Novavax (NASDAQ:NVAX), basically flat near $10.08. Moderna stock is the clear standout in the trio on the session.
The year-to-date scoreboard tells the same story. Moderna stock is up 95% , well ahead of Novavax at 50% and Pfizer at 5%. So yes, MRNA stock is outperforming both vaccine peers today and for the year so far.
Hantavirus Headlines Spark the Rally
The proximate catalyst behind today’s pop appears to be sentiment-driven. Reports of a recent cruise ship outbreak have renewed attention on Hantavirus, and Moderna’s early-stage research into an mRNA-based Hantavirus vaccine is pulling retail traders back into the name. Some are framing the setup as pandemic-era trading reminiscent of 2020.
Hantavirus is a rodent-borne virus that can cause Hantavirus Pulmonary Syndrome (HPS), with case fatality rates that can be high. Outbreaks have historically been geographically contained, so any commercial-scale vaccine demand would likely be limited. The headlines, however, have triggered a familiar meme-style trading pattern in MRNA stock.
Retail communities are actively debating whether this is a sustainable catalyst or short-lived sentiment. The case for caution is that discovery-stage vaccine programs rarely translate into near-term revenue. The case for continued momentum is that biotech sector rotation and technical breakouts appear to be reinforcing the move.
Fundamentals are quietly supporting the bid as well. Moderna posted a sizable Q1 2026 beat on May 1, with revenue of $389 million against the $236.36 million consensus. Management reaffirmed full-year guidance for up to 10% revenue growth and a year-end cash position of $4.5 billion to $5 billion.
CEO Stéphane Bancel asserted, “The Moderna team delivered a great start to the year, driving significant revenue growth and substantial cost reductions building on actions taken in 2025.” International product sales contributed $311 million versus $78 million in the U.S., a sign of renewed overseas COVID-19 demand.
Pfizer and Novavax Tell Different Stories
Pfizer stock trades as a diversified large-cap pharma equity, with vaccines (including Comirnaty in partnership with BioNTech) representing one product line among many. That breadth keeps Pfizer stock far less reactive to any single vaccine headline. Pfizer’s Q4 2025 report featured adjusted EPS of $0.66 and a roughly 7% dividend yield that anchors the equity for income-oriented holders.
Novavax sits at the opposite end of the spectrum. The recombinant protein-vaccine maker carries a market cap near $1.69 billion and has weathered multiple boom-bust cycles tied to COVID-era expectations. Novavax’s Q1 2026 results on May 6 included a $30 million upfront payment from a new Pfizer Matrix-M adjuvant license, with up to $500 million in potential milestones.
The smaller-cap name (Novavax) continues to trade with a higher beta to any vaccine-related catalyst, which can cut both ways for momentum chasers.
What to Watch Next
The next concrete Moderna catalyst is the August 5 Prescription Drug User Fee Act (PDUFA) date for the company’s seasonal flu vaccine, mRNA-1010. Approval would mark Moderna’s fifth commercial product and broaden the platform well beyond its COVID-19 franchise. Investors can find broader context in our recent biotech stocks coverage tracking the sector’s rotation winners.
The bull case rests on the mRNA platform’s breadth across flu, RSV, oncology, and rare disease programs, plus Phase 3 readouts due this year in norovirus and intismeran for melanoma. The bear case, meanwhile, is more sober. Moderna’s COVID-era revenue continues to normalize, GAAP losses remain wide (Q1 included an $878 million non-recurring litigation charge), and a single cruise ship outbreak doesn’t translate into commercial Hantavirus demand.
Moderna’s valuation has stretched alongside the run. Prudent investors may want to size positions modestly given MRNA’s volatility, especially after a 137% one-year gain. For broader pharma exposure with less single-headline risk, the Pfizer comparison remains worth tracking, and momentum traders are likely to stay active in MRNA into the close.
Top Gaining Stocks
Top Losing Stocks